Sign In
Buy CRTX
$2.20
+0 (+0%)
At Close: Nov 04, 2022
Cortexyme, a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases, today an
Stocks To Watch: Big Focus On Big Tech
08:26am, Saturday, 25'th Jul 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
Cortexyme Announces Upcoming Data Presentations at the Alzheimer’s Association International Conference 2020
12:00pm, Wednesday, 22'nd Jul 2020
Cortexyme, Inc. (Nasdaq: CRTX) today announced that its work to pioneer upstream therapeutic approaches to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases wi
Cortexyme Announces Upcoming Data Presentations at the Alzheimer’s Association International Conference 2020
12:00am, Wednesday, 22'nd Jul 2020
Cortexyme, Inc. (Nasdaq: CRTX) today announced that its work to pioneer upstream therapeutic approaches to improve the lives of patients diagnosed wit
Legal & General Group Plc Trims Position in Cortexyme, Inc. (NASDAQ:CRTX)
04:52am, Monday, 06'th Jul 2020
Legal & General Group Plc lessened its stake in Cortexyme, Inc. (NASDAQ:CRTX) by 22.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). Th
V&M Premium Portfolio: 2020 Mid-Year Report Card Through Week 26
01:58am, Monday, 29'th Jun 2020
The Premium Portfolio is up +14.43% YTD, while the benchmark S&P 500 Index is down -6.86% through June 26th. The Premium Portfolio has beaten the S&P 500 every
HC Wainwright Initiates Coverage on Cortexyme (NASDAQ:CRTX)
06:32am, Friday, 26'th Jun 2020
Analysts at HC Wainwright initiated coverage on shares of Cortexyme (NASDAQ:CRTX) in a research report issued to clients and investors on Wednesday, Marketbeat.com reports. The brokerage set a “buy�
Cortexyme (NASDAQ:CRTX) Stock Rating Lowered by Zacks Investment Research
01:38am, Friday, 26'th Jun 2020
Cortexyme (NASDAQ:CRTX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports
Citigroup Inc. Has $158,000 Stock Holdings in Cortexyme, Inc. (NASDAQ:CRTX)
06:34am, Thursday, 18'th Jun 2020
Citigroup Inc. increased its position in Cortexyme, Inc. (NASDAQ:CRTX) by 50.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commiss
Insider Weekends: Director Of Accelerate Diagnostics Adds To His Stock
01:20pm, Monday, 15'th Jun 2020
Insider buying decreased significantly last week. Notable Insider Buys: Accelerate Diagnostics, Inc., Keurig Dr Pepper Inc., Vishay Precision Group, Inc., Corte
4 Biotech Stocks That Are Seeing Big Buys in June
11:00am, Sunday, 14'th Jun 2020
Allogene Therapeutics, Personalis, Cortexyme, and La Jolla Pharmaceutical have all seen large stock purchases by insiders and big investors this month.
Hedge Funds Are Buying Cortexyme, Inc. (CRTX)
08:27pm, Friday, 12'th Jun 2020
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investmen
Cortexyme: A New Approach To Defeat Alzheimer's Disease (NASDAQ:CRTX)
07:14pm, Friday, 12'th Jun 2020
Alzheimer's disease remains an unbreakable wall for biotech companies for decades. The recent fails in beta-amyloid thesis create an opportunity for better unde
David Lamond Acquires 49,125 Shares of Cortexyme, Inc. (NASDAQ:CRTX) Stock
04:30am, Wednesday, 10'th Jun 2020
Cortexyme, Inc. (NASDAQ:CRTX) Director David Lamond acquired 49,125 shares of Cortexyme stock in a transaction that occurred on Thursday, June 4th. The stock was acquired at an average cost of $41.73
Cortexyme Announces "Atuzaginstat" Selected as First-in-Class Nonproprietary Name for COR388
12:00pm, Tuesday, 09'th Jun 2020
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with Alzheimer’s and other degenerati
